Respiratory Antiviral Treatment Market by Drug Class and Distribution Channel - Global Industry Analysis & Forecast to 2027
Published On : January 2021 Pages : 156 Category: Pharma & Healthcare Report Code : HC0215326
Respiratory Antiviral Treatment Market ByDrug Class (Nucleoside Analogs, Neuraminidase Inhibitors, Ion Channel Blockers, and Fusion Protein Inhibitors) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Respiratory Antiviral Treatment Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Respiratory Antiviralis a contagious infection of the upper respiratory tract that includes the nose, throat, pharynx, larynx, and bronchi.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Respiratory Antiviral Treatment Market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Mylan Inc.
- Merck & Co., Inc.
- AstraZeneca plc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Respiratory Antiviral Treatment Market, ByDrug Class, Estimates and Forecast, 2017-2027 ($Million)
o Nucleoside Analogs
o Neuraminidase Inhibitors
o Ion Channel Blockers
o Fusion Protein Inhibitors
· Respiratory Antiviral Treatment Market, ByDistribution Channel, Estimates and Forecast, 2017-2027 ($Million)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
· Respiratory Antiviral Treatment Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o F. Hoffmann-La Roche Ltd.
o Novartis AG
o Takeda Pharmaceutical Company Limited
o Pfizer, Inc.
o Teva Pharmaceutical Industries Ltd.
o Sun Pharmaceutical Industries Ltd.
o GlaxoSmithKline plc
o Mylan Inc.
o Merck & Co., Inc.
· Respiratory Antiviral Treatment Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Respiratory Antiviral Treatment Market, By Country
o U.S. Respiratory Antiviral Treatment Market
o Canada Respiratory Antiviral Treatment Market
o Mexico Respiratory Antiviral Treatment Market
o Europe
§ Europe Respiratory Antiviral Treatment Market, By Country
o UK Respiratory Antiviral Treatment Market
o Germany Respiratory Antiviral Treatment Market
o France Respiratory Antiviral Treatment Market
o Russia Respiratory Antiviral Treatment Market
o Italy Respiratory Antiviral Treatment Market
o Rest of Europe Respiratory Antiviral Treatment Market
o Asia-Pacific
§ Asia-Pacific Respiratory Antiviral Treatment Market, By Country
o China Respiratory Antiviral Treatment Market
o Japan Respiratory Antiviral Treatment Market
o South Korea Respiratory Antiviral Treatment Market
o India Respiratory Antiviral Treatment Market
o Southeast Asia Respiratory Antiviral Treatment Market
o Rest of Asia-Pacific Respiratory Antiviral Treatment Market
o South America
§ South America Respiratory Antiviral Treatment Market
o Brazil Respiratory Antiviral Treatment Market
o Argentina Respiratory Antiviral Treatment Market
o Columbia Respiratory Antiviral Treatment Market
o Rest of South America Respiratory Antiviral Treatment Market
o Middle East and Africa
§ Middle East and Africa Respiratory Antiviral Treatment Market
o Saudi Arabia Respiratory Antiviral Treatment Market
o UAE Respiratory Antiviral Treatment Market
o Egypt Respiratory Antiviral Treatment Market
o Nigeria Respiratory Antiviral Treatment Market
o South Africa Respiratory Antiviral Treatment Market
o TurkeyRespiratory Antiviral Treatment Market
o Rest of MEA Respiratory Antiviral Treatment Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Respiratory Antiviral Treatment Market, By Drug Class
5.1. Introduction
5.2. Global Respiratory Antiviral Treatment Revenue and Market Share by Drug Class (2017-2021)
5.2.1. Global Respiratory Antiviral Treatment Revenue and Revenue Share by Drug Class (2017-2021)
5.3. Nucleoside Analogs
5.3.1. Global Nucleoside Analogs Revenue and Growth Rate (2017-2021)
5.4. Neuraminidase Inhibitors
5.4.1. Global Neuraminidase Inhibitors Revenue and Growth Rate (2017-2021)
5.5. Ion Channel Blockers
5.5.1. Global Ion Channel Blockers Revenue and Growth Rate (2017-2021)
5.6. Fusion Protein Inhibitors
5.6.1. Global Fusion Protein Inhibitors Revenue and Growth Rate (2017-2021)
6. Respiratory Antiviral Treatment Market, By Distribution Channel
6.1. Introduction
6.2. Global Respiratory Antiviral Treatment Revenue and Market Share by Distribution Channel (2017-2021)
6.2.1. Global Respiratory Antiviral Treatment Revenue and Revenue Share by Distribution Channel (2017-2021)
6.3. Hospital Pharmacies
6.3.1. Global Hospital Pharmacies Revenue and Growth Rate (2017-2021)
6.4. Retail Pharmacies
6.4.1. Global Retail Pharmacies Revenue and Growth Rate (2017-2021)
6.5. Online Pharmacies
6.5.1. Global Online Pharmacies Revenue and Growth Rate (2017-2021)
7. Respiratory Antiviral Treatment Market, By Region
7.1. Introduction
7.2. Global Respiratory Antiviral Treatment Revenue and Market Share by Regions
7.2.1. Global Respiratory Antiviral Treatment Revenue by Regions (2017-2021)
7.3. North America Respiratory Antiviral Treatment by Countries
7.3.1. North America Respiratory Antiviral Treatment Revenue and Growth Rate (2017-2021)
7.3.2. North America Respiratory Antiviral Treatment Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Respiratory Antiviral Treatment by Countries
7.4.1. Europe Respiratory Antiviral Treatment Revenue and Growth Rate (2017-2021)
7.4.2. Europe Respiratory Antiviral Treatment Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Respiratory Antiviral Treatment by Countries
7.5.1. Asia-Pacific Respiratory Antiviral Treatment Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Respiratory Antiviral Treatment Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Respiratory Antiviral Treatment by Countries
7.6.1. South America Respiratory Antiviral Treatment Revenue and Growth Rate (2017-2021)
7.6.2. South America Respiratory Antiviral Treatment Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Respiratory Antiviral Treatment by Countries
7.7.1. Middle East and Africa Respiratory Antiviral Treatment Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Respiratory Antiviral Treatment Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. F. Hoffmann-La Roche Ltd.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Novartis AG
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Takeda Pharmaceutical Company Limited
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Pfizer, Inc.
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Teva Pharmaceutical Industries Ltd.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Sun Pharmaceutical Industries Ltd.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. GlaxoSmithKline plc
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Mylan Inc.
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Merck & Co., Inc.
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. AstraZeneca plc.
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.1. Global Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Respiratory Antiviral Treatment Market Forecast by Regions (2022-2027)
9.2.1. North America Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.1.1. United States Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.1.2. Canada Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.1.3. Mexico Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.2. Europe Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.2.1. Germany Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.2.2. France Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.2.3. UK Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.2.4. Russia Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.2.5. Italy Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.3. Asia-Pacific Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.3.1. China Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.3.2. Japan Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.3.3. Korea Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.3.4. India Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.4. South America Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.4.1. Brazil Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.4.2. Argentina Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.4.3. Columbia Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.4.4. Rest of South America Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.5. Middle East and Africa Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.5.3. Egypt Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.5.4. Nigeria Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.5.5. South Africa Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.5.6. Turkey Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Respiratory Antiviral Treatment Market Forecast (2022-2027)
9.3. Respiratory Antiviral Treatment Market Forecast by Drug Class (2022-2027)
9.3.1. Respiratory Antiviral Treatment Forecast by Drug Class (2022-2027)
9.3.2. Respiratory Antiviral Treatment Market Share Forecast by Drug Class (2022-2027)
9.4. Respiratory Antiviral Treatment Market Forecast by Distribution Channel (2022-2027)
9.4.1. Respiratory Antiviral Treatment Forecast by Distribution Channel (2022-2027)
9.4.2. Respiratory Antiviral Treatment Market Share Forecast by Distribution Channel (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Respiratory Antiviral Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Respiratory Antiviral Treatment Revenue and Revenue Share by Drug Class (2017-2019)
Figure Global Nucleoside Analogs Revenue and Growth Rate (2017-2019)
Figure Global Neuraminidase Inhibitors Revenue and Growth Rate (2017-2019)
Figure Global Ion Channel Blockers Revenue and Growth Rate (2017-2019)
Figure Global Fusion Protein Inhibitors Revenue and Growth Rate (2017-2019)
Table Global Respiratory Antiviral Treatment Revenue and Revenue Share by Distribution Channel (2017-2019)
Figure Global Hospital Pharmacies Revenue and Growth Rate (2017-2019)
Figure Global Retail Pharmacies Revenue and Growth Rate (2017-2019)
Figure Global Online Pharmacies Revenue and Growth Rate (2017-2019)
Table Global Respiratory Antiviral Treatment Revenue by Regions (2017-2019)
Figure North America Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure North America Respiratory Antiviral Treatment Revenue and Growth Rate (2017-2019)
Figure North America Respiratory Antiviral Treatment by Countries (2017-2019)
Figure North America Respiratory Antiviral Treatment Revenue (Million USD) by Countries (2017-2019)
Figure United States Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure United States Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Canada Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Mexico Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Europe Respiratory Antiviral Treatment Revenue and Growth Rate (2017-2019)
Figure Europe Respiratory Antiviral Treatment by Countries (2017-2019)
Figure Europe Respiratory Antiviral Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Germany Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Germany Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure France Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure UK Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Russia Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Italy Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Rest of Europe Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Asia-Pacific Respiratory Antiviral Treatment Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Respiratory Antiviral Treatment by Countries (2017-2019)
Figure Asia-Pacific Respiratory Antiviral Treatment Revenue (Million USD) by Countries (2017-2019)
Figure China Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure China Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Japan Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Korea Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure India Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Southeast Asia Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure South America Respiratory Antiviral Treatment Revenue and Growth Rate (2017-2019)
Figure South America Respiratory Antiviral Treatment by Countries (2017-2019)
Figure South America Respiratory Antiviral Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Brazil Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Argentina Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Columbia Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Rest of South America Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Middle East and Africa Respiratory Antiviral Treatment Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Respiratory Antiviral Treatment by Countries (2017-2019)
Figure Middle East and Africa Respiratory Antiviral Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Saudi Arabia Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure United Arab Emirates Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Egypt Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Nigeria Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure South Africa Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Turkey Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Respiratory Antiviral Treatment Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Table F. Hoffmann-La Roche Ltd. Respiratory Antiviral Treatment Financial Overview
Table Novartis AG Respiratory Antiviral Treatment Financial Overview
Table Takeda Pharmaceutical Company Limited Respiratory Antiviral Treatment Financial Overview
Table Pfizer, Inc. Respiratory Antiviral Treatment Financial Overview
Table Teva Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Financial Overview
Table Sun Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Financial Overview
Table GlaxoSmithKline plc Respiratory Antiviral Treatment Financial Overview
Table Mylan Inc. Respiratory Antiviral Treatment Financial Overview
Table Merck & Co., Inc. Respiratory Antiviral Treatment Financial Overview
Table AstraZeneca plc. Respiratory Antiviral Treatment Financial Overview
Figure Global Respiratory Antiviral Treatment Revenue (Millions USD) and Growth Rate (2019-2027)
Table Respiratory Antiviral Treatment Market Forecast by Regions (2019-2027)
Figure North America Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure United States Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Canada Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Mexico Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Europe Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Germany Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure France Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure UK Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Russia Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Italy Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Rest of Europe Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Asia-Pacific Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure China Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Japan Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Korea Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure India Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Southeast Asia Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure South America Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Brazil Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Argentina Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Columbia Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Rest of South America Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Middle East and Africa Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Saudi Arabia Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure United Arab Emirates Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Egypt Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Nigeria Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure South Africa Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Turkey Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Respiratory Antiviral Treatment Market Forecast (2019-2027)
Figure Global Respiratory Antiviral Treatment Forecast by Drug Class (2019-2027)
Figure Global Respiratory Antiviral Treatment Market Share Forecast by Drug Class (2019-2027)
Figure Global Respiratory Antiviral Treatment Forecast by Drug Class (2019-2027)
Figure Global Respiratory Antiviral Treatment Forecast by Distribution Channel (2019-2027)
Figure Global Respiratory Antiviral Treatment Market Share Forecast by Distribution Channel (2019-2027)
Figure Global Respiratory Antiviral Treatment Forecast by Distribution Channel (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|